OrthoPediatrics Corp. Stock 12‑Month Price Target Raised to $29, Implies 22% Upside

What happened

The average 12-month price target for OrthoPediatrics Corp. stock rose from $27.5 to $29, based on estimates from 8 analysts, with forecasts ranging from $23 to $35 per share. The updated target implies about 22% upside from the Oct. 27 closing price.

Confirmed

Global impact / market context

A higher average target means analysts on balance expect the stock to be worth more in a year. For a beginner, this signals growing analyst confidence, though targets are opinions, not guarantees, and the wide $23 to $35 range shows real disagreement about the company's prospects.

Analyst inference

The consensus rating stays at Buy across 8 analysts, split into 7 Buys, 1 Hold and 0 Sells. That combination of a raised target and a strong Buy tilt suggests analysts see the stock's recent price as undervalued relative to their expected earnings path.

Analyst inference

What to watch

1. Watch whether the $29 average target keeps rising or starts falling as analysts update estimates, since the current range spans $23 to $35 per share and reflects differing views. Confirmed
2. Monitor whether the 7 Buys and 1 Hold shift after the company's next earnings report, because rating changes can move the stock more than target tweaks alone. Proposed
3. Track OrthoPediatrics' revenue growth and spending on new products, since analyst targets rest on future profit expectations that depend on sales execution and cost control. Analyst inference

Evidence

• Original source link unavailable